WO2006024024A3 - Solid and crystalline ibandronate sodium and processes for preparation thereof - Google Patents

Solid and crystalline ibandronate sodium and processes for preparation thereof Download PDF

Info

Publication number
WO2006024024A3
WO2006024024A3 PCT/US2005/030500 US2005030500W WO2006024024A3 WO 2006024024 A3 WO2006024024 A3 WO 2006024024A3 US 2005030500 W US2005030500 W US 2005030500W WO 2006024024 A3 WO2006024024 A3 WO 2006024024A3
Authority
WO
WIPO (PCT)
Prior art keywords
solid
processes
preparation
ibandronate sodium
crystalline ibandronate
Prior art date
Application number
PCT/US2005/030500
Other languages
French (fr)
Other versions
WO2006024024A2 (en
Inventor
Revital Lifshitz-Liron
Thomas Bayer
Judith Aronhime
Original Assignee
Teva Pharma
Teva Pharmaceutical Usa Inc
Revital Lifshitz-Liron
Thomas Bayer
Judith Aronhime
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35968334&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2006024024(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EP05791142A priority Critical patent/EP1713489B1/en
Priority to CA002576659A priority patent/CA2576659A1/en
Priority to JP2006536948A priority patent/JP4559431B2/en
Priority to ES05791142T priority patent/ES2358269T3/en
Priority to AT05791142T priority patent/ATE495747T1/en
Application filed by Teva Pharma, Teva Pharmaceutical Usa Inc, Revital Lifshitz-Liron, Thomas Bayer, Judith Aronhime filed Critical Teva Pharma
Priority to DE602005025977T priority patent/DE602005025977D1/en
Priority to CNA2005800285039A priority patent/CN101022812A/en
Priority to DE202005021414U priority patent/DE202005021414U1/en
Publication of WO2006024024A2 publication Critical patent/WO2006024024A2/en
Publication of WO2006024024A3 publication Critical patent/WO2006024024A3/en
Priority to IL181298A priority patent/IL181298A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Secondary Cells (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Artificial Filaments (AREA)
  • Battery Electrode And Active Subsutance (AREA)
  • Liquid Crystal Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)

Abstract

The present invention relates to solid amorphous and crystalline forms of ibandronate sodium.
PCT/US2005/030500 2004-08-23 2005-08-23 Solid and crystalline ibandronate sodium and processes for preparation thereof WO2006024024A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
DE202005021414U DE202005021414U1 (en) 2004-08-23 2005-08-23 Solid and crystalline ibandronate sodium
CA002576659A CA2576659A1 (en) 2004-08-23 2005-08-23 Solid and crystalline ibandronate sodium and processes for preparation thereof
JP2006536948A JP4559431B2 (en) 2004-08-23 2005-08-23 Solid and crystalline ibandronate sodium and process for its preparation
ES05791142T ES2358269T3 (en) 2004-08-23 2005-08-23 CRYSTAL FORM OF THE SOUND IBANDRONATE AND PROCEDURES FOR PREPARATION.
AT05791142T ATE495747T1 (en) 2004-08-23 2005-08-23 CRYSTALLINE FORM OF IBANDRONATE SODIUM AND PRODUCTION PROCESS THEREOF
EP05791142A EP1713489B1 (en) 2004-08-23 2005-08-23 Crystalline form of ibandronate sodium and processes for preparation thereof
DE602005025977T DE602005025977D1 (en) 2004-08-23 2005-08-23 CRYSTALLINE FORM OF IBANDRONATE SODIUM AND METHOD OF MANUFACTURING THEREOF
CNA2005800285039A CN101022812A (en) 2004-08-23 2005-08-23 Solid and crystalline ibandronate sodium and processes for preparation thereof
IL181298A IL181298A (en) 2004-08-23 2007-02-13 Solid and crystalline ibandronate sodium and processes for preparation thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60402604P 2004-08-23 2004-08-23
US60/604,026 2004-08-23
US69086705P 2005-06-16 2005-06-16
US60/690,867 2005-06-16

Publications (2)

Publication Number Publication Date
WO2006024024A2 WO2006024024A2 (en) 2006-03-02
WO2006024024A3 true WO2006024024A3 (en) 2006-06-29

Family

ID=35968334

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/030500 WO2006024024A2 (en) 2004-08-23 2005-08-23 Solid and crystalline ibandronate sodium and processes for preparation thereof

Country Status (12)

Country Link
US (1) US7563918B2 (en)
EP (2) EP1713489B1 (en)
JP (1) JP4559431B2 (en)
KR (2) KR20070043043A (en)
CN (1) CN101022812A (en)
AT (2) ATE520406T1 (en)
CA (1) CA2576659A1 (en)
DE (2) DE602005025977D1 (en)
ES (1) ES2358269T3 (en)
IL (1) IL181298A (en)
PT (2) PT1930011E (en)
WO (1) WO2006024024A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3395338T3 (en) 2003-09-12 2019-10-31 Amgen Inc Rapid dissolution formulation of cinacalcet hcl
BRPI0607092A2 (en) 2005-02-01 2009-08-04 Hoffmann La Roche 3- (n-methyl-n-pentyl) amino-1-hydroxypropane-1,1-diphosphonic acid monosodium salt monohydrate crystalline polymorph, process for the preparation of a crystalline ibandronate polymorph, and pharmaceutical composition which understand
CA2594717C (en) * 2005-02-01 2015-01-20 F. Hoffmann-La Roche Ag Ibandronate polymorph b
WO2007074475A2 (en) * 2005-12-27 2007-07-05 Natco Pharma Limited Novel polymorphic forms of ibandronate
EP2046342A4 (en) * 2006-07-28 2011-05-04 Reddys Lab Ltd Dr Crystalline form a of ibandronic acid and process for the preparation
JP2009516004A (en) * 2006-11-16 2009-04-16 テバ ファーマシューティカル インダストリーズ リミティド Crystal form of ibandronate sodium
CA2570949A1 (en) * 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
BRPI0809548A8 (en) 2007-04-11 2018-10-16 Hoffmann La Roche Process for the preparation of the monosodium acid- (monohydrate) -3- (n-methyl-n-pentyl) amino-1-hydroxypropane-1,1-diphosphonic salt
AU2008242788A1 (en) 2007-04-19 2008-10-30 Dr. Reddy's Laboratories Ltd. Ibandronate sodium polymorphs
WO2009020483A1 (en) * 2007-08-09 2009-02-12 Teva Pharmaceutical Industries Ltd. Crystalline forms of ibandronate sodium
WO2009053445A2 (en) * 2007-10-26 2009-04-30 Chemo Ibérica, S.A. Polymorphic forms of ibandronate sodium and processes for preparation thereof
EP2128166A1 (en) 2008-05-20 2009-12-02 Chemo Ibérica, S.A. Polymorphic forms of Ibandronate sodium and processes for preparation thereof
WO2009061336A1 (en) * 2007-11-05 2009-05-14 Teva Pharmaceutical Industries Ltd. Amorphous and crystalline forms of ibandronate disodium
EP2180003A1 (en) 2008-10-21 2010-04-28 Zentiva, k.s. Preparation of ibandronate trisodium
US9192316B2 (en) 2009-05-15 2015-11-24 Nox Medical Systems and methods using flexible capacitive electrodes for measuring biosignals
WO2011016738A1 (en) 2009-08-05 2011-02-10 Zaklady Farmaceutyczne Polpharma Sa A process for the synthesis of 1-hydroxy-3-(n-methylpentylamino) propylidene bisphosphonic acid monosodium salt, monohydrate
ES2688925T3 (en) 2010-01-27 2018-11-07 Viiv Healthcare Company Antiviral treatment
US9059532B2 (en) 2010-06-25 2015-06-16 Nox Medical Biometric belt connector
US9598472B2 (en) 2010-09-03 2017-03-21 Valneva Austria Gmbh Isolated polypeptide of the toxin A and toxin B proteins of C. difficile and uses thereof
AR085689A1 (en) 2011-03-07 2013-10-23 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITIONS OF METFORMIN, LINAGLIPTINE AND AN SGLT-2 INHIBITOR
WO2013179305A1 (en) * 2012-06-01 2013-12-05 Hetero Research Foundation Ibandronate sodium solid dispersion
EP2981532A4 (en) 2013-04-01 2016-12-14 Hetero Research Foundation Process for pomalidomide
WO2015068041A1 (en) 2013-11-06 2015-05-14 Nox Medical Method, apparatus, and system for measuring respiratory effort
AR099354A1 (en) 2013-11-15 2016-07-20 Akebia Therapeutics Inc SOLID FORMS OF ACID {[5- (3-CHLOROPHENYL) -3-HYDROXIPIRIDIN-2-CARBON] AMINO} ACETIC, COMPOSITIONS, AND ITS USES
EP3500155A1 (en) 2016-08-19 2019-06-26 Nox Medical Method, apparatus, and system for measuring respiratory effort of a subject
WO2018220606A1 (en) 2017-06-02 2018-12-06 Nox Medical Ehf Coherence-based method, apparatus, and system for identifying corresponding signals of a physiological study
EP3678543A1 (en) 2017-09-08 2020-07-15 Nox Medical System and method for non-invasively determining an internal component of respiratory effort

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4927814A (en) * 1986-07-11 1990-05-22 Boehringer Mannheim Gmbh Diphosphonate derivatives, pharmaceutical compositions and methods of use
WO2005063779A2 (en) * 2003-12-23 2005-07-14 Lyogen Limited A process for the preparation of alkyl- and aryl-diphosphonic acids and salts thereof
WO2006002348A2 (en) * 2004-06-23 2006-01-05 Teva Pharmaceutical Industies Ltd. Solid and crystalline ibandronic acid

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2639721B2 (en) 1988-12-27 1997-08-13 富士重工業株式会社 Combustion chamber of internal combustion engine
US5652227A (en) * 1995-01-30 1997-07-29 Teronen; Olli Pekka Inhibition of the degradation of connective tissue matrix protein components in mammals
DE19637890A1 (en) * 1996-09-17 1998-03-19 Max Planck Gesellschaft Liposomal medicament containing bi:phosphonic acid salt,
DE19828450A1 (en) * 1998-06-26 1999-12-30 Hassan Jomaa Use of bisphosphonic acid compounds and autoantigens or allergens
EP0998933A1 (en) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Process for producing pharmaceutical compositions containing diphosphonates for oral administration
EP0998932A1 (en) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Solid pharmaceutical dosage form containing diphosphonates or their salts and method for its production
PL351674A1 (en) * 1999-05-21 2003-05-19 Novartis Ag Use of bisphosphonic acids for treating angiogenesis
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
JP3923800B2 (en) * 2000-05-05 2007-06-06 エフ．ホフマン−ラ ロシュ アーゲー Gel-like pharmaceutical composition for subcutaneous administration comprising bisphosphonic acid or a salt thereof
EP1296689B3 (en) * 2000-06-20 2013-02-13 Novartis AG Method of administering bisphosphonates
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
EP1228761A3 (en) * 2001-02-01 2003-01-15 Riderway Corporation Liquid pharmaceutical composition for treating bone diseases
ITMI20020908A1 (en) 2002-04-29 2003-10-29 Chemi Spa ALENDRONATE SODIUM PREPARATION PROCESS
MXPA04009586A (en) * 2002-05-10 2005-01-11 Hoffmann La Roche Bisphosphonic acid for the treatment and prevention of osteoporosis.
BR0310087A (en) * 2002-05-17 2005-08-16 Wyeth Corp Hyaluronic acid injectable solid carriers for application of osteogenic proteins
SI1596870T2 (en) * 2002-12-20 2011-07-29 Hoffmann La Roche High dose ibandronate formulation
BRPI0607092A2 (en) 2005-02-01 2009-08-04 Hoffmann La Roche 3- (n-methyl-n-pentyl) amino-1-hydroxypropane-1,1-diphosphonic acid monosodium salt monohydrate crystalline polymorph, process for the preparation of a crystalline ibandronate polymorph, and pharmaceutical composition which understand
CA2594717C (en) 2005-02-01 2015-01-20 F. Hoffmann-La Roche Ag Ibandronate polymorph b
WO2007074475A2 (en) 2005-12-27 2007-07-05 Natco Pharma Limited Novel polymorphic forms of ibandronate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4927814A (en) * 1986-07-11 1990-05-22 Boehringer Mannheim Gmbh Diphosphonate derivatives, pharmaceutical compositions and methods of use
WO2005063779A2 (en) * 2003-12-23 2005-07-14 Lyogen Limited A process for the preparation of alkyl- and aryl-diphosphonic acids and salts thereof
WO2006002348A2 (en) * 2004-06-23 2006-01-05 Teva Pharmaceutical Industies Ltd. Solid and crystalline ibandronic acid

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CAIRA M R: "Crystalline polymorphism of organic compounds", TOPICS IN CURRENT CHEMISTRY, vol. 198, 1998, pages 163 - 208, XP001156954, ISSN: 0340-1022 *
CRAIG D Q M ET AL: "The relevance of the amorphous state to pharmaceutical dosage forms: Glassy drugs and freeze dried systems", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 179, no. 2, 15 March 1999 (1999-03-15), pages 179 - 207, XP002274233, ISSN: 0378-5173 *
HANCOCK B C ET AL: "Characteristics and significance of the amorphous state in pharmaceutical systems", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 86, no. 1, January 1997 (1997-01-01), pages 1 - 12, XP000929450, ISSN: 0022-3549 *
MONIER-FAUGERE M-C ET AL: "A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs", JOURNAL OF BONE AND MINERAL RESEARCH, vol. 8, no. 11, 1993, pages 1345 - 1355, XP009064673, ISSN: 0884-0431 *

Also Published As

Publication number Publication date
JP2007512237A (en) 2007-05-17
ATE495747T1 (en) 2011-02-15
US20070179119A1 (en) 2007-08-02
WO2006024024A2 (en) 2006-03-02
EP1930011A3 (en) 2008-06-18
ATE520406T1 (en) 2011-09-15
EP1930011B1 (en) 2011-08-17
PT1930011E (en) 2011-09-16
IL181298A (en) 2011-04-28
KR20090120011A (en) 2009-11-23
CN101022812A (en) 2007-08-22
CA2576659A1 (en) 2006-03-02
IL181298A0 (en) 2007-07-04
ES2358269T3 (en) 2011-05-09
US7563918B2 (en) 2009-07-21
EP1713489A2 (en) 2006-10-25
DE602005025977D1 (en) 2011-03-03
EP1713489B1 (en) 2011-01-19
DE202005021414U1 (en) 2008-03-20
EP1930011A2 (en) 2008-06-11
PT1713489E (en) 2011-03-03
JP4559431B2 (en) 2010-10-06
KR20070043043A (en) 2007-04-24

Similar Documents

Publication Publication Date Title
WO2006024024A3 (en) Solid and crystalline ibandronate sodium and processes for preparation thereof
WO2007127292A3 (en) Tigeycline crystalline forms and processes for preparation thereof
WO2008066935A3 (en) Crystalline forms of tigecycline and processes for preparation thereof
WO2006012379A8 (en) Processes for preparation of crystalline mycophenolate sodium
IL188330A0 (en) Processes for the preparation of
TWI367257B (en) Process for the preparation of 2-butanol
WO2006131591A3 (en) An entacapone-containing oral dosage form
WO2006136357A3 (en) Crystalline modifications to pyraclostrobin
WO2007076245A3 (en) Novel hydrogen sulfate salt
WO2005062897A3 (en) Polymorphs of ezetimibe and processes for the preparation thereof
WO2008021342A3 (en) Amorphous and crystalline forms of 9-hydroxy-risperidone ( paliperidone )
WO2008083130A3 (en) Amorphous and crystalline form a of carvedilol phosphate
ZA200800729B (en) A crystalline form of the zoledronic acid, a process to obtain it and the pharmaceutical composition comprising it
WO2008088779A3 (en) Solid state forms of 5-azacytidine and processes for preparation thereof
WO2008021346A3 (en) Pure paliperidone and processes for preparing thereof
IL184945A0 (en) Crystalline forms of pregabalin
IL177561A0 (en) Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols
EP1883619B8 (en) Process of preparation of substituted tetrafluorobenzylaniline compound and its pharmaceutically approved salts
WO2006105482A3 (en) Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same
WO2010006904A3 (en) Crystalline forms of rabeprazole sodium
WO2007099552A3 (en) Novel crystalline form of atovastatin hemi-magnesium
WO2010027848A3 (en) Forms of lapatinib compounds and processes for the preparation thereof
WO2006053625A8 (en) Crystalline form of cefdinir ammonium salt as an intermediate for the preparation of pure cefdinir
IL186499A (en) Processes for the preparation of crystalline atorvastatin hemicalcium form
WO2008014510A3 (en) Crystalline form a of ibandronic acid and process for the preparation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2005791142

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006536948

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2005791142

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 555/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2576659

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 181298

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/002286

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 200580028503.9

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 1020077005922

Country of ref document: KR